The Brokerages Expect Esperion Therapeutics Inc (ESPR) Will Announce Earnings of -$1.73 Per Share

The Brokerages Expect Esperion Therapeutics Inc (ESPR) Will Announce Earnings of -$1.73 Per Share

According to Zacks, analysts expect that Esperion Therapeutics will report full year earnings of ($6.86) per share for the current financial year, with EPS estimates ranging from ($7.36) to ($6.54). For the next fiscal year, analysts expect that the firm will report earnings of ($4.96) per share, with EPS estimates ranging from ($5.46) to ($4.38). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Esperion Therapeutics.

Analysts predict that Esperion Therapeutics Inc (NASDAQ:ESPR) will post ($1.73) earnings per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Esperion Therapeutics’ earnings, with the lowest EPS estimate coming in at ($1.82) and the highest estimate coming in at ($1.63). Esperion Therapeutics posted earnings per share of ($0.62) during the same quarter last year, which indicates a negative year-over-year growth rate of 179%. The firm is expected to announce its next earnings results on Thursday, August 3rd.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Monday, May 1st. The biopharmaceutical company reported ($1.80) EPS for the quarter, missing the consensus estimate of ($1.44) by $0.36. During the same period in the prior year, the company posted ($0.65) earnings per share. ESPR has been the topic of a number of research reports. Needham & Company LLC set a $25.00 price objective on Esperion Therapeutics and gave the stock a “buy” rating in a research report on Saturday, February 4th. ValuEngine upgraded Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday. Zacks Investment Research upgraded Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, March 2nd. JPMorgan Chase & Co. restated a “hold” rating and set a $50.00 price objective (up previously from $22.00) on shares of Esperion Therapeutics in a research report on Monday, March 20th. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $30.00 price objective (up previously from $20.00) on shares of Esperion Therapeutics in a research report on Thursday, February 23rd. Eight analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $33.39.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Monday, May 1st. The biopharmaceutical company reported ($1.80) EPS for the quarter, missing the consensus estimate of ($1.44) by $0.36. During the same period in the prior year, the company posted ($0.65) earnings per share. In other news, Director Dov A. Md Goldstein sold 800,000 shares of the business’s stock in a transaction dated Wednesday, March 22nd. The stock was sold at an average price of $41.66, for a total value of $33,328,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Gilbert S. Omenn acquired 1,000 shares of the company’s stock in a transaction dated Tuesday, March 21st. The stock was acquired at an average cost of $42.26 per share, for a total transaction of $42,260.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at $422,600. The disclosure for this purchase can be found here. 35.40% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Quantbot Technologies LP acquired a new position in shares of Esperion Therapeutics during the first quarter worth about $158,000. Keybank National Association OH acquired a new position in shares of Esperion Therapeutics during the fourth quarter worth about $159,000. C WorldWide Group Holding A S acquired a new position in shares of Esperion Therapeutics during the first quarter worth about $162,000. Elkfork Partners LLC acquired a new position in shares of Esperion Therapeutics during the fourth quarter worth about $169,000. Finally, Princeton Alpha Management LP acquired a new position in shares of Esperion Therapeutics during the first quarter worth about $205,000. 64.65% of the stock is currently owned by institutional investors. Shares of Esperion Therapeutics (ESPR) traded up 4.71% during trading on Tuesday, hitting $33.98. The stock had a trading volume of 654,574 shares. The stock’s market capitalization is $767.61 million. The stock has a 50 day moving average price of $35.48 and a 200-day moving average price of $24.40. Esperion Therapeutics has a one year low of $9.40 and a one year high of $48.21.

About Esperion Therapeutics Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:ESPR”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Get a free copy of the Zacks research report on Esperion Therapeutics (ESPR) For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment